PMID: 9527146Apr 4, 1998Paper

Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo

Journal of Neurology, Neurosurgery, and Psychiatry
M KoskiniemiJ Taalas

Abstract

To compare the efficacy, tolerability, and safety of three daily dosage regimens of oral piracetam in patients with progressive myoclonus epilepsy. Twenty patients (12 men, eight women), aged 17-43 years, with classical Unverricht-Lundborg disease were enrolled in a multicentre, randomised, double blind trial of crossover design in which the effects of daily doses of 9.6 g, 16.8 g, and 24 g piracetam, given in two divided doses, were compared with placebo. The crossover design was such that patients received placebo and two of the three dosage regimens of piracetam, each for two weeks, for a total treatment period of six weeks and thus without wash out between each treatment phase. The primary outcome measure was a sum score representing the adjusted total of the ratings of six components of a myoclonus rating scale in which stimulus sensitivity, motor impairment, functional disability, handwriting, and global assessments by investigators and patients were scored. Sequential clinical assessments were made by the same neurologist in the same environment at the same time of day. Treatment with 24 g/day piracetam produced significant and clinically relevant improvement in the primary outcome measure of mean sum score (p=0.005) and...Continue Reading

References

Oct 6, 1979·Lancet·R L Bick
Jan 1, 1976·Neurology·M A Goldberb, J D Dorman
May 2, 1992·Lancet·A MalafosseA de la Chapelle
Mar 1, 1990·Neurology·K J MeadorD W King
Jan 1, 1988·Movement Disorders : Official Journal of the Movement Disorder Society·D D Truong, S Fahn
Jul 31, 1986·The New England Journal of Medicine·S F BerkovicL S Wolfe
Dec 1, 1988·Clinical Neuropharmacology·J A ObesoC D Marsden
Aug 1, 1987·Journal of Clinical Psychopharmacology·C R WilsherP Overby
Apr 1, 1982·Archives of Neurology·M Iivanainen, J J Himberg
Jan 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·P BrownC D Marsden
Feb 1, 1993·Neurology·B CroisileM Billardon
Jan 24, 1997·Biochemical Pharmacology·W E MüllerR Bartsch
Jun 1, 1963·Epilepsia· VAN HEYCOPTENHAMM, H DE JAGER

❮ Previous
Next ❯

Citations

Nov 30, 2000·Current Treatment Options in Neurology·S Frucht
Dec 6, 2001·Current Treatment Options in Neurology·Basim M. Uthman, Andreas Reichl
Apr 9, 2005·Current Treatment Options in Neurology·Melissa J Nirenberg, Steven J Frucht
Jun 27, 2008·Current Treatment Options in Neurology·Victoria C Chang, Steven J Frucht
Mar 29, 2001·Journal of Clinical Psychopharmacology·C FehrA Szegedi
Aug 14, 1999·Epilepsia·A E Lehesjoki, M Koskiniemi
Jul 20, 2005·Epilepsia·Yahya Agha KhaniEva Andermann
Mar 8, 2008·Epilepsia·Reetta KälviäinenEsa Mervaala
Jul 5, 2006·Biological & Pharmaceutical Bulletin·Enver AltasYavuz Sutbeyaz
Jul 14, 2012·Drug, Healthcare and Patient Safety·Amy Z CrepeauElaine C Wirrell
Jun 10, 2010·CNS Drugs·Thomas S Monaghan, Norman Delanty
Dec 14, 2001·Lancet·S Shorvon
Sep 17, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·John N Caviness
Jun 27, 2002·Expert Opinion on Investigational Drugs·Christian G BienHeinz Wiendl
Jul 31, 2004·Epilepsia·Joan A Conry
Feb 16, 2005·Epilepsy & Behavior : E&B·Ebru AykutluAyşen Gökyigit
Apr 4, 2016·Current Treatment Options in Neurology·Ariel Levy, Robert Chen
Jul 21, 2015·International Wound Journal·Elif Sari, Gungor C Dincel
Feb 28, 2015·Practical Neurology·Naveed MalekJohn Greene
Aug 25, 2004·Seizure : the Journal of the British Epilepsy Association·S Pradeep Kumar, Philip E M Smith
Nov 16, 2014·Current Neurology and Neuroscience Reports·Kelly Mills, Zoltan Mari
Sep 24, 2004·Lancet Neurology·John N Caviness, Peter Brown
Jun 9, 2009·Brain & Development·Hamit OzyurekDuygu Belkis Bas
Jan 10, 2017·Expert Opinion on Pharmacotherapy·Pasquale Striano, Vincenzo Belcastro
Mar 30, 2005·Journal of Child Neurology·Federico Vigevano
Jul 24, 2018·Expert Review of Neurotherapeutics·Shweta Bhat, Subramaniam Ganesh
Jul 12, 2005·CNS Drug Reviews·Bengt Winblad
Mar 16, 2019·Expert Review of Neurotherapeutics·Christine M Stahl, Steven J Frucht
Nov 21, 2018·Journal of Neurology, Neurosurgery, and Psychiatry·James W Lance, Sophie E Waller
Sep 14, 2012·The Cochrane Database of Systematic Reviews·Stefano RicciEnrico Righetti
Nov 1, 2001·The Cochrane Database of Systematic Reviews·J GreenerR Whurr
Mar 11, 2020·Expert Review of Neurotherapeutics·Antonella RivaPasquale Striano
Jul 9, 2010·The Cochrane Database of Systematic Reviews·Chamila Geeganage, Philip Mw Bath
Jan 16, 2020·Paediatric Drugs·Gregory L Holmes
Sep 11, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ashley B Pena, John N Caviness

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.